Thromboembolic Complications Related to Central Venous Access Catheters in Cancer Patients

 

 Buy Article Permissions and Reprints

ABSTRACT

Recent well-designed, prospective, controlled trials have demonstrated a lower incidence of catheter-related deep vein thrombosis (CRDVT) compared with earlier studies but this complication remains an important limitation to the delivery of drugs and supportive care to cancer patients. Prophylaxis of CRDVT with antithrombotic agents was not supported by recent prospective randomized trials, and its routine use is not recommended. Larger studies will be required to determine if cancer patients at particularly high risk for CRDVT can benefit from prophylaxis with antithrombotic agents. There are no prospective controlled studies to guide the therapy of CRDVT but treatment with anticoagulants remains the mainstay of therapy. Although recently published guidelines might help standardize the therapy of patients with CRDVT, prospective controlled studies are needed to determine the optimal therapy of this important complication of central venous catheters in cancer patients.

REFERENCES

• 1 Hoshal Jr V L, Ause R G, Hoskins P A. Fibrin sleeve formation of indwelling subclavian central venous catheters.  Arch Surg. 1971;  102 253-258
  PubMedGoogle Scholar
• 2 Balestreri L, De Cicco M, Matovic M et al.. Central venous catheter-related thrombosis in clinically asymptomatic oncologic patients: a phlebographic study.  Eur J Radiol. 1995;  20 108-111
  CrossrefPubMedGoogle Scholar
• 3 De Cicco M, Matovic M, Balestreri L et al.. Central venous thrombosis: an early and frequent complication in cancer patients bearing long-term silastic catheter. A prospective study.  Thromb Res. 1997;  86 101-113
  CrossrefPubMedGoogle Scholar
• 4 Xiang D Z, Verbeken E K, van Lommel A T et al.. Composition and formation of the sleeve enveloping a central venous catheter.  J Vasc Surg. 1998;  28 260-271
  CrossrefPubMedGoogle Scholar
• 5 Forauer A R, Theoharis C G, Dasika N L. Jugular vein catheter placement: histologic features and development of catheter-related (fibrin) sheaths in a swine model.  Radiology. 2006;  240 427-434
  CrossrefPubMedGoogle Scholar
• 6 Starkhammar H, Bengtsson M, Morales O. Fibrin sleeve formation after long-term brachial catheterization, with implantable port device. A prospective venographic study.  Eur J Surg. 1992;  158 481-484
  PubMedGoogle Scholar
• 7 Raad I I, Luna M, Khalil S A et al.. The relationship between the thrombotic and infectious complications of central venous catheters.  JAMA. 1994;  271 1014-1016
  CrossrefPubMedGoogle Scholar
• 8 Hurtubise M R, Bottino J C, Lawson M et al.. Restoring patency of occluded central venous catheters.  Arch Surg. 1980;  115 212-213
  PubMedGoogle Scholar
• 9 Hooke C. Recombinant tissue plasminogen activator for central venous access device occlusion.  J Pediatr Oncol Nurs. 2000;  17 174-178
  CrossrefPubMedGoogle Scholar
• 10 Stephens L C, Haire W D, Kotulak G D. Are clinical signs accurate indicators of the cause of central venous catheter occlusion?.  JPEN J Parenter Enteral Nutr. 1995;  19 75-79
  PubMedGoogle Scholar
• 11 Schifferdecker B, Shaw J A, Piemonte T C, Eisenhauer A C. Nonmalignant superior vena cava syndrome. Pathophysiology and management.  Catheter Cardiovasc Interv. 2005;  65 416-442
  PubMedGoogle Scholar
• 12 Monreal M, Lafoz E, Ruiz J et al.. Upper extremity deep venous thrombosis and pulmonary embolism. A prospective study.  Chest. 1991;  99 280-283
  CrossrefPubMedGoogle Scholar
• 13 Prandoni P, Bernardi E, Marchiori A et al.. The long-term clinical course of acute deep vein thrombosis of the arm: prospective cohort study.  BMJ. 2004;  329 484-485
  CrossrefPubMedGoogle Scholar
• 14 Bernardi E, Pesavento R, Prandoni P. Upper extremity deep vein thrombosis.  Semin Thromb Hemost. 2006;  32 729-736
  Article in Thieme ConnectPubMedGoogle Scholar
• 15 Agnelli G, Verso M. Therapy insight: venous-catheter-related thrombosis in cancer patients.  Nat Clin Pract Oncol. 2006;  3 214-222
  CrossrefPubMedGoogle Scholar
• 16 Bozzetti F, Scarpa D, Terno G J et al.. Subclavian venous thrombosis due to indwelling catheters: a prospective study on 52 patients.  JPEN J Parenter Enteral Nutr. 1983;  7 560-562
  PubMedGoogle Scholar
• 17 Lokich J J, Becker B. Subclavian vein thrombosis in patients treated with infusion chemotherapy for advanced malignancy.  Cancer. 1983;  52 1586-1589
  PubMedGoogle Scholar
• 18 Bern M M, Lokich J J, Wallach S R et al.. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial.  Ann Intern Med. 1990;  112 423-428
  CrossrefPubMedGoogle Scholar
• 19 Monreal M, Alastrue A, Rull M et al.. Upper extremity deep venous thrombosis in cancer patients with venous access devices-prophylaxis with a low molecular weight heparin (Fragmin).  Thromb Haemost. 1996;  75 251-253
  PubMedGoogle Scholar
• 20 Horne III M K, May D J, Alexander H R et al.. Venographic surveillance of tunneled venous access devices in adult oncology patients.  Ann Surg Oncol. 1995;  2 174-178
  PubMedGoogle Scholar
• 21 Barzaghi A, Dell'Orto M, Rovelli A et al.. Central venous catheter clots: incidence, clinical significance and catheter care in patients with hematologic malignancies.  Pediatr Hematol Oncol. 1995;  12 243-250
  PubMedGoogle Scholar
• 22 Glaser D W, Medeiros D, Rollins N, Buchanan G R. Catheter-related thrombosis in children with cancer.  J Pediatr. 2001;  138 255-259
  CrossrefPubMedGoogle Scholar
• 23 Haire W D, Lieberman R P, Edney J et al.. Hickman catheter-induced thoracic vein thrombosis. Frequency and long-term sequelae in patients receiving high-dose chemotherapy and marrow transplantation.  Cancer. 1990;  66 900-908
  CrossrefPubMedGoogle Scholar
• 24 Kuter D J. Thrombotic complications of central venous catheters in cancer patients.  Oncologist. 2004;  9 207-216
  CrossrefPubMedGoogle Scholar
• 25 Couban S, Goodyear M, Burnell M et al.. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer.  J Clin Oncol. 2005;  23 4063-4069
  CrossrefPubMedGoogle Scholar
• 26 Lee A Y, Levine M N, Butler G et al.. Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer.  J Clin Oncol. 2006;  24 1404-1408
  CrossrefPubMedGoogle Scholar
• 27 Biffi R, De Braud F, Orsi F et al.. A randomized, prospective trial of central venous ports connected to standard open-ended or Groshong catheters in adult oncology patients.  Cancer. 2001;  92 1204-1212
  CrossrefPubMedGoogle Scholar
• 28 Verso M, Agnelli G, Bertoglio S et al.. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo controlled, randomized study in cancer patients.  J Clin Oncol. 2005;  23 4057-4062
  CrossrefPubMedGoogle Scholar
• 29 Karthaus M, Kretzchmar A, Kroning A et al.. Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial.  Ann Oncol. 2006;  17 289-296
  PubMedGoogle Scholar
• 30 Levine M, Kakkar A K. Catheter-associated thrombosis: thromboprophylaxis or not?.  J Clin Oncol. 2005;  23 4006-4008
  CrossrefPubMedGoogle Scholar
• 31 Prandoni P, Polistena P, Bernardi E et al.. Upper extremity deep vein thrombosis. Risk factors, diagnosis and complications.  Arch Intern Med. 1997;  157 57-62
  CrossrefPubMedGoogle Scholar
• 32 Koksoy C, Kuzu A, Kutlay J et al.. The diagnostic value of colour Doppler ultrasound in central venous catheter related thrombosis.  Clin Radiol. 1995;  50 687-689
  PubMedGoogle Scholar
• 33 Gaitini D, Beck-Razi N, Haim N, Brenner B. Prevalence of upper extremity deep venous thrombosis diagnosed by color duplex sonography in cancer patients with central venous catheters.  J Ultrasound Med. 2006;  25 1297-1303
  PubMedGoogle Scholar
• 34 Male C, Chait P, Ginsberg J S et al.. Comparison of venography and ultrasound for the diagnosis of asymptomatic deep vein thrombosis in the upper body of children: results of the PARKAA study.  Thromb Haemost. 2002;  87 593-598
  PubMedGoogle Scholar
• 35 Kroencke T J, Taupitz M, Arnold R, Fritsche L, Hamm B. Three-dimensional gadolinium-enhanced magnetic resonance venography in suspected thrombo-occlusive disease of the central chest veins.  Chest. 2001;  120 1570-1576
  CrossrefPubMedGoogle Scholar
• 36 Thornton M J, Ryan R, Varghese J C et al.. A three-dimensional gadolinium-enhanced MR venography technique for imaging central veins.  AJR Am J Roentgenol. 1999;  173 999-1003
  PubMedGoogle Scholar
• 37 Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients.  J Clin Oncol. 2003;  21 3665-3675
  CrossrefPubMedGoogle Scholar
• 38 Adess M, Eisner R, Nand S et al.. Thromboembolism in cancer patients: pathogenesis and treatment.  Clin Appl Thromb Hemost. 2006;  12 254-266
  PubMedGoogle Scholar
• 39 Fijnheer R, Paijmans B, Verdonck L F et al.. Factor V Leiden in central venous catheter-associated thrombosis.  Br J Haematol. 2002;  118 267-270
  CrossrefPubMedGoogle Scholar
• 40 Riordan M, Weiden P L. Factor V Leiden mutation does not account for central venous catheter-related thrombosis.  Am J Hematol. 1998;  58 150-152
  CrossrefPubMedGoogle Scholar
• 41 Mandala M, Curigliano G, Bucciarelli P et al.. Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter.  Ann Oncol. 2004;  15 590-593
  CrossrefPubMedGoogle Scholar
• 42 Abdelkefi A, Ben Romdhane N, Kriaa A et al.. Prevalence of inherited prothrombotic abnormalities and central venous catheter-related thrombosis in haematopoietic stem cell transplant recipients.  Bone Marrow Transplant. 2005;  36 885-889
  CrossrefPubMedGoogle Scholar
• 43 Tesselaar M E, Ouwerkerk J, Nooy M A et al.. Risk factors for catheter-related thrombosis in cancer patients.  Eur J Cancer. 2004;  40 2253-2259
  CrossrefPubMedGoogle Scholar
• 44 Mandala M, Curigliano G, Bucciarelli P et al.. Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter.  Ann Oncol. 2004;  15 590-593
  CrossrefPubMedGoogle Scholar
• 45 van Rooden C J, Rosendaal F R, Meinders A E et al.. The contribution of factor V Leiden and prothrombin G20210A mutation to the risk of central venous catheter-related thrombosis.  Haematologica. 2004;  89 201-206
  PubMedGoogle Scholar
• 46 Wermes C, von Depka Prondzinski M, Lichtinghagen R et al.. Clinical relevance of genetic risk factors for thrombosis in paediatric oncology patients with central venous catheters.  Eur J Pediatr. 1999;  158(suppl 3) S43-146
  PubMedGoogle Scholar
• 47 Eastman M E, Khorsand M, Maki D G et al.. Central venous device-related infection and thrombosis in patients treated with moderate dose continuous-infusion interleukin-2.  Cancer. 2001;  91 806-814
  CrossrefPubMedGoogle Scholar
• 48 Stephens L C, Haire W D, Schmit-Pokorny K, Kessinger A, Kotulac G. Granulocyte macrophage colony stimulating factor: high incidence of apheresis catheter thrombosis during peripheral stem cell collection.  Bone Marrow Transplant. 1993;  11 51-54
  PubMedGoogle Scholar
• 49 Borow M, Crowley J G. Evaluation of central venous catheter thrombogenicity.  Acta Anaesthesiol Scand Suppl. 1985;  81 59-64
  PubMedGoogle Scholar
• 50 Eastridge B J, Lefor A T. Complications of indwelling venous access devices in cancer patients.  J Clin Oncol. 1995;  13 233-238
  PubMedGoogle Scholar
• 51 Brown-Smith J K, Stoner M H, Barley Z A. Tunneled catheter thrombosis: factors related to incidence.  Oncol Nurs Forum. 1990;  17 543-549
  PubMedGoogle Scholar
• 52 Craft P S, May J, Dorigo A, Hoy C, Plant A. Hickman catheters: left sided insertion, male gender and obesity are associated with an increased risk of complications.  Aust N Z J Med. 1996;  26 33-39
  PubMedGoogle Scholar
• 53 Male C, Chait P, Andrew M et al.. Central venous line-related thrombosis in children: association with central venous line location and insertion technique.  Blood. 2003;  101 4273-4278
  CrossrefPubMedGoogle Scholar
• 54 McBride K D, Fisher R, Warnock N et al.. A comparative analysis of radiological and surgical placement of central venous catheters.  Cardiovasc Intervent Radiol. 1997;  20 17-22
  CrossrefPubMedGoogle Scholar
• 55 van Rooden C J, Schippers E F, Barge R M et al.. Infectious complications of central venous catheters increase the risk of catheter-related thrombosis in hematology patients: a prospective study.  J Clin Oncol. 2005;  23 2655-2660
  PubMedGoogle Scholar
• 56 Journeycake J M, Buchanan G R. Catheter-related deep venous thrombosis and other complications in children with cancer.  J Clin Oncol. 2006;  24 4575-4580
  CrossrefPubMedGoogle Scholar
• 57 Trerotola S O, Kuhn-Fulton J, Johnson M S et al.. Tunneled infusion catheters: increased incidence of symptomatic venous thrombosis after subclavian versus internal jugular venous access.  Radiology. 2000;  217 89-93
  CrossrefPubMedGoogle Scholar
• 58 MacDonald S, Watt A J, McNally D, Edwards R D, Moss J G. Comparison of technical success and outcome of tunneled catheters inserted via the jugular and subclavian approaches.  J Vasc Interv Radiol. 2000;  11 225-231
  CrossrefPubMedGoogle Scholar
• 59 Nightingale C E, Norman A, Cunningham D et al.. A prospective analysis of 949 long-term central venous access catheters for ambulatory chemotherapy in patients with gastrointestinal malignancy.  Eur J Cancer. 1997;  33 398-403
  CrossrefPubMedGoogle Scholar
• 60 Bern M M, Lokich J J, Wallach S R et al.. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial.  Ann Intern Med. 1990;  112 423-428
  CrossrefPubMedGoogle Scholar
• 61 Boraks P, Seale J, Price J et al.. Prevention of central venous catheter associated thrombosis using minidose warfarin in patients with hematologic malignancies.  Br J Haematol. 1998;  101 483-486
  CrossrefPubMedGoogle Scholar
• 62 Heaton D C, Han D Y, Inder A. Minidose (1 mg) warfarin as prophylaxis for central vein catheter thrombosis.  Intern Med J. 2002;  32 84-88
  PubMedGoogle Scholar
• 63 Mismetti P, Mille D, Laporte S et al.. Low-molecular-weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: a pilot randomized trial.  Haematologica. 2003;  88 67-73
  PubMedGoogle Scholar
• 64 Agnelli G, Verso M. Is antithrombotic prophylaxis required in cancer patients with central venous catheters? No.  J Thromb Haemost. 2006;  4 14-15
  CrossrefPubMedGoogle Scholar
• 65 Levine M. Is antithrombotic prophylaxis required in cancer patients with central venous catheters? Still an open question.  J Thromb Haemost. 2006;  4 16-18
  CrossrefPubMedGoogle Scholar
• 66 Huisman M V. Is antithrombotic prophylaxis required in cancer patients with central venous catheters? Yes for special patient groups.  J Thromb Haemost. 2006;  4 10-13
  CrossrefPubMedGoogle Scholar
• 67 Timoney J P, Malkin M G, Leone D M et al.. Safe and cost effective use of alteplase for the clearance of occluded central venous devices.  J Clin Oncol. 2002;  20 1918-1922
  CrossrefPubMedGoogle Scholar
• 68 Haire W D, Deitcher S R, Mullane K M et al.. Recombinant urokinase for restoration of patency in occluded central venous access devices. A double-blind, placebo-controlled trial.  Thromb Haemost. 2004;  92 575-582
  PubMedGoogle Scholar
• 69 Moll S, Kenyon P, Bertoli L et al.. Phase II trial of alfimeprase, a novel-acting fibrin degradation agent, for occluded venous devices.  J Clin Oncol. 2006;  24 3056-3060
  CrossrefPubMedGoogle Scholar
• 70 Linenberger M L. Catheter-related thrombosis: risks, diagnosis and management.  J Natl Compr Canc Netw. 2006;  4 889-901
  PubMedGoogle Scholar
• 71 Savage K J, Wells P S, Schulz V et al.. Outpatient use of low molecular weight heparin (Dalteparin) for the treatment of deep vein thrombosis of the upper extremity.  Thromb Haemost. 1999;  82 1008-1010
  PubMedGoogle Scholar
• 72 Frank D A, Meuse J, Hirsch D, Ibrahim J G, van den Abbeele A D. The treatment and outcome of cancer patients with thromboses on central venous catheters.  J Thromb Thrombolysis. 2000;  10 271-275
  CrossrefPubMedGoogle Scholar
• 73 Sabeti S, Schillinger M, Miekusch W, Haumer M, Ahmadi R, Minar E. Treatment of subclavian-axillary thrombosis: long-term outcome of anticoagulation versus thrombosis.  Thromb Res. 2002;  108 279-285
  CrossrefPubMedGoogle Scholar
• 74 Spence L D, Gironta M G, Malde H M et al.. Acute upper extremity deep vein thrombosis: safety and effectiveness of superior venal cava filters.  Radiology. 1999;  210 53-58
  PubMedGoogle Scholar
• 75 Ascher E, Hingorani A, Mazzariol F et al.. Clinical experience with superior vena caval Greenfield filters.  J Endovasc Surg. 1999;  6 365-369
  CrossrefPubMedGoogle Scholar
• 76 Wagman L D, Baird M F, Bennett C L et al.. Venous thromboembolic disease. Clinical practice guidelines in oncology.  J Natl Compr Canc Netw. 2006;  4 838-869
  PubMedGoogle Scholar

César O FreytesM.D. 

Mail Code 7880, 7703 Floyd Curl Drive

San Antonio, TX 78229-3900

Email: freytes@uthscsa.edu